At OC Wellness, we prescribe the No DAC (Drug Affinity Complex) formulation of CJC-1295 also known as Modified GRF (1-29)
GLOW carries no Drug Identification Number, no Natural Product Number, and no Homeopathic Drug Number, and none of the three component peptides (GHK-Cu, BPC-157, TB-500) has received market authorization for human or veterinary use in Canada
Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer
In short, CAIL wants to give skin back its 20-year-old appearance

Body Composition and Metabolic Parameters Research on component peptides revealed favorable effects on body composition and metabolic markers[10]: Significant reductions in waist circumference (10-15 cm reductions observed) Preferential visceral fat loss documented through imaging studies Preserved lean body mass relative to total weight loss in most studies Improved body composition ratios with fat mass reductions exceeding total weight loss percentages Type 2 Diabetes Research Glycemic Control Studies Investigations in type 2 diabetes models demonstrated robust glucose-lowering effects[11]: HbA1c reductions of 2.0-2.4% observed with GLP3 in phase 2 diabetes trials Fasting plasma glucose reductions of 40-60 mg/dL documented across dose ranges Improved continuous glucose monitoring parameters including time in range and glucose variability CagriSema combination achieved superior glycemic control compared to individual components Studies showed that 72% of participants with prediabetes reverted to normoglycemia with GLP3 treatment, suggesting potential diabetes prevention applications[12]
